<div class="entities" style="line-height: 2.5; direction: ltr">Admission Date:  [**2184-7-7**]              Discharge Date:   [**2184-8-12**]<br><br>Date of Birth:  [**2139-8-7**]             Sex:   F<br><br>Service: MEDICINE<br><br>Allergies:<br>Patient recorded as having No Known Allergies to 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Drugs
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
<br><br>Attending:[**First Name3 (LF) 20640**]<br>Chief Complaint:<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Hematuria
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br><br>Major Surgical or Invasive Procedure:<br>Cystoscopy<br>Angiogram of the left kidney<br><br>History of Present Illness:<br>Ms. [**Known lastname 59777**] is a 44 year old female with a history of recently<br>diagnosed 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    stage
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    IV
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    non
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>

<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>

<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    small
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    cell
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lung
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    metastatic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 to<br>brain, adrenals, and kidneys who presents with complaints of<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    blood
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 when she urinates. She notes that she first noticed this<br>two days ago. She also notes 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    with
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    urination
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 since she<br>noticed the blood. She ntes it has been the worst between 1 am<br>and 5 am where she can't leave the BR due to constant need to<br>urinate. She also urinates several times during the day.  Each<br>time is extremely painful. She notes that since the bleeding<br>began, the pain has begun to improve but the bleeding has<br>continued at the same frequency.  She denies any vaginal<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    bleeding
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
, 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    melena
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
, 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hematochezia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
, or 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hematemesis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.<br><br>In the [**Hospital1 18**] ED, 98.3, 108/70, 96, 18, 100% 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    RA
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.  While in the ED<br>she was noted to have 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    frank
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hematuria
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. Pelvic exam was performed<br>without evidence of vaginal or cervical bleeding. No obvious GI<br>bleeding was noted. She was guiaic negative. Labs were<br>remarkable for Hct drop from 34-&gt;20 over 1 month. Coags, WBC,<br>and plts normal. Electrolytes showed new renal failure with<br>BUN/Cr 46/2.3 from 14/0.6 1 month prior. K was 6.0, bicarb 17.<br>U/A revealed &gt;50 RBCs, 21-50 WBCs, LE and nitrite negative, and<br>no bacteria.   She received 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    30
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    grams
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 of 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    kayexalate
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    10
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 of<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    dexamethasone
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    zofran
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, and 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    morphine
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
.  Prior to floor transfer,<br>she lost her IV access. Bilateral femoral CVLs were attempted<br>but wire could not be passed. She then had a successful R IJ CVL<br>placement.<br><br>Currently, she feels well.  Episode of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    frank
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hematuria
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 witnessed<br>upon arrival to the floor, also notable for 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    stringlike
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    clot
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. On<br>ROS, she denies any fevers, chills, chest pain, SOB, DOE.  She<br>does note increased 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 and recent poor po intake. She also<br>notes intermittent 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    nausea
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-ADE</span>
</mark>
 when taking her medications.  She<br>denies any numbness or tingling, weakness, or confusion. Denies<br>any 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    muscle
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 or 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    joint
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pains
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 which the exception of chronic R thumb<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 which improved with 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    steroids
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 and has worsened with 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    taper
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>
.<br>All other ROS negative.<br><br>Past Medical History:<br># 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    stage
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    IV
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    non
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>

<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>

<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    small
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    cell
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lung
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 metastatic to brain,<br>adrenals, kidneys (see below)<br># h/o 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    intermittent
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    asthma
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br># h/o 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    tooth
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    infection
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 &amp; extraction between [**2184-2-15**].<br># History of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    subluxation
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    of
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    the
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    metaphalangeal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    joint
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 in<br>[**2178-6-17**].<br># Prior history of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.<br><br>Past Oncologic history:<br>Initially presented in [**2-/2184**] with complaints of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    weight
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    loss
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
,<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    nausea
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 and 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    vomiting
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.  It seems that her symptoms were initially<br>mild.  She did not have shortness of breath, cough or other<br>complaints at that time.  By [**3-/2184**], she continued to lose<br>weight and was found to have a potential right-sided dental<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    abscess
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.  She was treated for that empirically with 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    antibiotics
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
<br>and continued to have weight 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    loss
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
, 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    diarrhea
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.  It seems that in<br>the end of [**Month (only) 958**] and beginning of [**5-/2184**], the patient<br>represented to medical attention with mild shortness of<br>breath with 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    exertion
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 and 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    chest
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    discomfort
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.  She also had noted<br>at that point subjective 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    low
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-ADE</span>
</mark>
-grade temperatures and some 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    cough
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>productive of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    brown
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    sputum
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.  In [**5-/2184**], she already had a<br>20-pound 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    weight
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    loss
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.  During the initial presentation, she also<br>complained of one episode of 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hemoptysis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-ADE</span>
</mark>
 with production of more<br>than 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    one
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    teaspoon
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>
 of 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    blood
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
. Due to the above-mentioned symptoms,<br>the patient underwent a computer tomography of the chest on<br>[**2184-5-14**] that disclosed a 2.6 cm cavitary lesion in the<br>posterior right upper lobe with additional smaller right-sided<br>pulmonary nodules and extensive right hilar lymphadenopathy with<br>marked 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    narrowing
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    of
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    the
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hilar
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    airways
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 and vessels. At that<br>point, further staging imaging was obtained with a computer<br>tomography of the torso on [**2184-5-29**] that disclosed the chest<br>findings as detailed above.  There was also right upper lobe<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pulmonary
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    interstitial
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    thickening
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
, which was worrisome for<br>lymphangitic spread.  There was a subtle sclerosis of the T4<br>vertebral body.  There was no evidence of extrathoracic disease.<br> The adrenals had 2 cm masses.  There were multiple enlarged<br>retroperitoneal lymph nodes measuring up to 1.3 cm. An MRI of<br>head was performed on [**2184-5-29**] and showed multiple areas of<br>enhancement identifying with surrounding 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    edema
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    in
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 both cerebral<br>hemispheres as well as in the posterior fossa.  The largest<br>lesion measured 1.5 cm in the left frontal lobe. The patient had<br>had some intermittent 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    headaches
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 that were thought to be<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    migraines
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 at that point.  However, she had no problems with<br>motor strength up to the time of initial MRI when she developed<br>some gait 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    instability
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 and required a cane.  She also complained<br>of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    intermittent
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    blurry
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    vision
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.  She was diagnosed the etiology<br>of the 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    brain
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lesions
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.  A brain biopsy was performed on<br>[**2184-5-30**].  Multiple fragments were obtained.  All showed small<br>nests of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    large
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    cell
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    undifferentiated
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    carcinoma
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 throughout brain<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lesions
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.  D cells were positive for CK7 and TTF1. Due to the<br>presence of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    nonsmall
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    cell
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lung
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    with
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    brain
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    metastasis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 and<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    edema
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
, the patient was referred to neurooncology and radiation<br>oncology.  Whole brain radiation was started on [**2184-6-5**].  The<br>patient received 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    3000
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    cGy
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>
 to the brain.  She was also started on<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    dexamethasone
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
.  Her last day of radiation was [**2184-6-15**].  She has<br>most recently been on a 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    steroid
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    taper
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>
. She is currently in the<br>planning stages of palliative 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    chemotherapy
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
.<br><br>Social History:<br>Lives in [**Location 1411**] with fiance and three children. The patient<br>started smoking 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    cigarettes
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 at age 13. ~45-pack-year history.  No<br>history of alcohol use.  She has a remote history of prior<br>
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    intravenous
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 drug use and 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    cocaine
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 use.  Originally from Sicily.<br>Moved to USA in [**2135**]. She worked as a domestic cleaner and had<br>some exposure to areas affected by 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    asbestos
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 and 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    heavy
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    chemicals
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Drug</span>
</mark>
.<br> She currently is out of work and living with family members.<br><br>Family History:<br>Mother, grandfather, and grandmother with 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    DM
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. Father passed away<br>at 76 due to &quot;natural causes&quot;. Mother is 76. [**Name2 (NI) **] maternal<br>grandfather had a diagnosis of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    stomach
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.  Her paternal<br>grandfather had a diagnosis of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    prostate
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.<br><br>Physical Exam:<br>T: 97.6 BP: 138/70, HR: 103, RR: 20 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    O2
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 98% RA<br>Gen: Pleasant, chronically ill appearing female, NAD<br>HEENT: +
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Alopecia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.  MMM. OP clear.<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    NECK
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
: Supple. JVP low. R IJ CDI<br>CV: RRR. nl S1, S2. No murmurs, rubs or [**Last Name (un) 549**]<br>LUNGS: CTAB<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ABD
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
: NABS. Soft, NT, ND.  No HSM<br>EXT: WWP, NO CCE. Full distal pulses<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    SKIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
: No rashes/lesions, ecchymoses.<br>NEURO: A&amp;Ox3. Appropriate. CN 2-12 grossly intact. Moving all<br>extremities. Normal gait.<br><br><br>Pertinent Results:<br>[**2184-7-7**] 08:28PM   GLUCOSE-111* UREA N-46* CREAT-2.3*#<br>SODIUM-132* POTASSIUM-6.0* CHLORIDE-99 TOTAL CO2-17* ANION<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    GAP
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    22
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
*<br>[**2184-7-7**] 08:28PM   ALT(SGPT)-29 AST(SGOT)-17 LD(LDH)-350*<br>CK(CPK)-24* ALK PHOS-58 TOT BILI-0.2 DIR BILI-0.1 INDIR BIL-0.1<br>[**2184-7-7**] 08:28PM   
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ALBUMIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
3.4<br>[**2184-7-7**] 08:28PM   OSMOLAL-290<br>[**2184-7-7**] 08:28PM   WBC-9.5 RBC-2.29*# HGB-6.9*# HCT-20.0*#<br>MCV-87 MCH-30.2 MCHC-34.5 RDW-17.3*<br>[**2184-7-7**] 08:28PM   NEUTS-82.0* LYMPHS-14.6* MONOS-1.5* EOS-1.7<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    BASOS
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-0.3<br>[**2184-7-7**] 08:28PM   PLT COUNT-215<br>[**2184-7-7**] 08:28PM   PT-12.4 PTT-23.1 INR(PT)-1.1<br>[**2184-7-7**] 08:30PM 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    URINE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
  BLOOD-LG NITRITE-NEG PROTEIN-500<br>GLUCOSE-NEG KETONE-NEG 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    BILIRUBIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-NEG UROBILNGN-NEG PH-6.5<br>LEUK-NEG<br>[**2184-7-7**] 08:30PM URINE  RBC-&gt;50 WBC-21-50* BACTERIA-NONE<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    YEAST
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    NONE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 EPI-0<br><br>Imaging:<br>========<br>CXR ([**7-10**]):<br>IMPRESSION: Development of focal area of increased density in<br>the right mid<br>lung consistent with 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    atelectasis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 or 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    consolidation
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. PA and<br>lateral views may<br>be helpful for further evaluation.<br><br>Renal US [**7-9**]:<br>1. Multiple bilateral hypoechoic renal masses, consistent with<br>known<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    metastases
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.<br>2. Doppler ultrasound demonstrates rapid systolic 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    upstrokes
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
,<br>with impaired<br>diastolic flow, and elevated resistive 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    indices
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. The main renal<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    veins
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 are<br>patent. These findings most likely reflect increased vascular<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    resistance
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>secondary to mass effect of multiple 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    metastatic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lesions
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. There<br>is no evidence for 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    renal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    vein
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    thrombosis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.<br><br>CXR [**7-8**]:<br>Tip of the new right internal jugular line projects over the low<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    SVC
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.<br>Mediastinal widening and right hilar enlargement due to<br>adenopathy are stable. No pneumothorax or pleural effusion.<br>Lungs are grossly clear. Heart size normal.<br><br>ECG [**7-7**]: NSR @ 83.  Nl axis and intervals. Isolated &lt; 1 mm STE<br>in 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    aVF
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. Compared to prior [**2184-5-30**], no sig change.<br><br>renal u/s [**7-7**]: Both kidneys enlarged and heterogeneous. Both<br>contain multiple masses with indistinct borders, some appear<br>hypervascular. No hydronephrosis. Echogenic 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lesion
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    in
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    bladder
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br>likely representing 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    blood
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    clot
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.<br><br>Pelvic US [**7-7**]:<br><br>CT torso [**6-30**]:<br>1. Slight decrease in the size of right upper 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lobe
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lung
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 nodules.<br>There has been no substantial change in the appearance of the<br>hilar and mediastinal lymphadenopathy.<br>2. Slight increase in the size of the bilateral 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    adrenal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lesions
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.<br><br>3. Increase in confluence and increase in size of some of the<br>bilateral renal lesions. Retroperitoneal and mesenteric<br>lymphadenopathy as before.<br><br>[**6-30**] bone scan:<br>No evidence of osseous metastatic disease. Abnormal uptake in<br>the<br>kidneys bilaterally. Recommend correlation with additional<br>anatomic imaging, such as ultrasound, as clinically indicated.<br><br><br>Brief Hospital Course:<br>44F with 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    metastatic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    NSCLC
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 (brain, bilat adrenals, bilat kidneys)<br>p/w frank 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hematuria
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
, anemia, renal failure. The bleeding was<br>from renal mets and was localized to the L kidney based on blood<br>seen coming from the L ureter at cystoscopy. The renal failure<br>was believed to be due to a combination of 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ATN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, mets, and<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    contrast
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
. Ultimately she was started on HD. The L kidney was<br>embolized to prevent 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    further
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    bleeding
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. She is now HD dependent.<br>Her hospitalization has been further complicated by 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pneumonia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>and 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    adrenal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    insufficiency
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.<br><br>Ultimately, after a trial of dialysis, the pt opted to be CMO.<br>However, when she did not pass over a weekend, she considered<br>this a sign that she could live longer and possbily survive<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. A family meeting was convened and an accommodation was<br>achieved wherein we would restart 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    abx
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 and try to relieve her of<br>her 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    anasarca
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 using either 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    diuretics
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 or ultrafiltration. That<br>said, after failing 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    diuretics
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 and prolonged difficulties with<br>the dialysis catheter, another meeting was convened. 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Antibiotics
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
<br>were stopped again and the patient was returned to [**Location 3225**] with<br>ultrafiltration. During an ultrafiltration treatment, she went<br>into respiratory failure and passed.<br><br>Medications on Admission:<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    albuterol
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    prn
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    dexamethasone
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    1
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    four
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Frequency</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    times
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Frequency</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Frequency</span>
</mark>
 (decreased [**7-5**], due to drop<br>to 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    2
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
 [**7-12**])<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    keppra
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    1000
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 [**Hospital1 **]<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lisinopril
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    10
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lorazepam
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    1
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    qhs
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Frequency</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    prn
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    nystatin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    swish
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
 and spit<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    protonix
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    40
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ranitidine
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    150
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 [**Hospital1 **]<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    tylenol
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    prn
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br><br>Discharge Medications:<br>none<br><br>Discharge Disposition:<br>Home with Service<br><br>Discharge Diagnosis:<br>Primary -<br>
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Hematuria
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-ADE</span>
</mark>
 likely from a 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    bleeding
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    kidney
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    metastasis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Metastatic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    non
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>

<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>

<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    small
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    cell
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lung
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    carcinoma
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Acute
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    renal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    failure
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 requiring initiation of dialysis<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Acute
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    blood
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-ADE</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    loss
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    anemia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Hyperkalemia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Hyponatremia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br><br><br>Discharge Condition:<br>deceased<br><br>Discharge Instructions:<br>You were admitted to the hospital due to 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hematuria
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-ADE</span>
</mark>
 and 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    low
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    blood
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
<br>counts.  You were given multiple 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    blood
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    transfusions
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 and<br>eventually your 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hematuria
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 stopped.  You were found to have acute<br>renal failure and eventually needed to be placed on dialysis.<br>You developed 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pneumonia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 and received 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    antibiotics
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 for that.<br>Finally, you received your first cycle of 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    chemotherapy
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
.<br><br>Please take your medications as ordered.<br><br>Call your primary doctor, or go to the emergency room if you<br>experience fevers, chills, 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    shortness
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    of
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-ADE</span>
</mark>
 breath, 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    chest
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
,<br>recurrent hematuria, dizziness, 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    blood
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    in
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    your
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    stool
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
, dark black<br>stool, or other concerning symptoms.<br><br>Followup Instructions:<br>n/a<br><br><br><br>Completed by:[**2184-8-12**]</div>